European Urology:局限性高级别前列腺癌中PSA水平无法线性预测患者预后

2020-07-19 Muse Fan MedSci原创

前列腺癌是一种雄激素高度依赖的肿瘤,对雄激素剥夺治疗(androgen deprivation therapy, ADT)非常敏感,前列腺特异性抗原(prost

     前列腺癌是一种雄激素高度依赖的肿瘤,对雄激素剥夺治疗(androgen deprivation therapy, ADT)非常敏感,前列腺特异性抗原(prostate specific antigen, PSA)作为受雄激素受体AR正调控的下游基因,通常在高级别前列腺癌中水平较高,但临床存在一部分前列腺癌病人恶性程度很高而PSA水平却非常低。这种高级别前列腺癌低PSA水平的临床和生物学意义都尚不明确。之前有研究表明在局限性高级别前列腺癌患者中,低水平PSA与中等水平的PSA病人相比预后更差。考虑到前列腺癌的病程发展较缓慢,但该研究的随访时间仅为2-4年,因此,对这一部分局限性高级别前列腺癌中低PSA水平与预后的关系需要进一步研究和验证。

     近日,发表在《European Urology》的一篇论文对1988-2015年间确诊的716名Gleason评分为8-10分的局限性前列腺癌患者的PSA水平与预后进行了分析。Gleason评分是根据腺体分化程度和肿瘤的生长形式来评估肿瘤恶性程度的一种组织学分级系统:Gleason2-4分属于分化良好癌,5-7分属于中等分化癌,8-10分为分化差或未分化癌。

     结果如上图所示:与具有中等PSA水平(5–8 ng / ml)的患者相比,低PSA(<5 ng / mL)的患者更容易发展为致死性前列腺癌,风险比为1.83;高PSA(> 8 ng / mL)的患者也比中等PSA的患者具有更高的致死性前列腺癌风险;而在整个队列研究中,低PSA和高PSA水平的患者均较中等PSA水平的患者具有更高的全因死亡率。

     研究得出:在高级别局限性前列腺癌患者中,PSA水平与致死率呈现J型曲线而非线性的关系。该研究提示,临床定义高风险前列腺癌时需要慎重考虑此类低水平PSA的局限性前列腺癌患者,对此类患者的基因改变和治疗方案选择也需要进一步研究。

 

文章出处:

Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, et al. Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. European Urology 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=909434, encodeId=ec94909434c1, content=说明那些低psa的是神经内分泌前列腺癌啊 tNEPC, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/fc552b42cd154706bb2cf25baecb02b2/554ea371740144a7a40f1dcfdbfbbc91.jpg, createdBy=e1942565806, createdName=12571bd1m76暂无昵称, createdTime=Sat Dec 19 20:19:36 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728600, encodeId=09d21e28600d1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 17 15:37:51 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692144, encodeId=790f16921441f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Feb 22 01:37:51 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924048, encodeId=df721924048f9, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue May 25 09:37:51 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271086, encodeId=b74b12e108688, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 21 06:37:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040787, encodeId=a18b1040e8732, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jul 19 18:37:51 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-12-19 12571bd1m76暂无昵称

    说明那些低psa的是神经内分泌前列腺癌啊 tNEPC

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=909434, encodeId=ec94909434c1, content=说明那些低psa的是神经内分泌前列腺癌啊 tNEPC, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/fc552b42cd154706bb2cf25baecb02b2/554ea371740144a7a40f1dcfdbfbbc91.jpg, createdBy=e1942565806, createdName=12571bd1m76暂无昵称, createdTime=Sat Dec 19 20:19:36 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728600, encodeId=09d21e28600d1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 17 15:37:51 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692144, encodeId=790f16921441f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Feb 22 01:37:51 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924048, encodeId=df721924048f9, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue May 25 09:37:51 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271086, encodeId=b74b12e108688, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 21 06:37:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040787, encodeId=a18b1040e8732, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jul 19 18:37:51 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-12-17 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=909434, encodeId=ec94909434c1, content=说明那些低psa的是神经内分泌前列腺癌啊 tNEPC, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/fc552b42cd154706bb2cf25baecb02b2/554ea371740144a7a40f1dcfdbfbbc91.jpg, createdBy=e1942565806, createdName=12571bd1m76暂无昵称, createdTime=Sat Dec 19 20:19:36 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728600, encodeId=09d21e28600d1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 17 15:37:51 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692144, encodeId=790f16921441f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Feb 22 01:37:51 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924048, encodeId=df721924048f9, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue May 25 09:37:51 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271086, encodeId=b74b12e108688, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 21 06:37:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040787, encodeId=a18b1040e8732, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jul 19 18:37:51 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=909434, encodeId=ec94909434c1, content=说明那些低psa的是神经内分泌前列腺癌啊 tNEPC, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/fc552b42cd154706bb2cf25baecb02b2/554ea371740144a7a40f1dcfdbfbbc91.jpg, createdBy=e1942565806, createdName=12571bd1m76暂无昵称, createdTime=Sat Dec 19 20:19:36 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728600, encodeId=09d21e28600d1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 17 15:37:51 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692144, encodeId=790f16921441f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Feb 22 01:37:51 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924048, encodeId=df721924048f9, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue May 25 09:37:51 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271086, encodeId=b74b12e108688, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 21 06:37:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040787, encodeId=a18b1040e8732, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jul 19 18:37:51 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=909434, encodeId=ec94909434c1, content=说明那些低psa的是神经内分泌前列腺癌啊 tNEPC, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/fc552b42cd154706bb2cf25baecb02b2/554ea371740144a7a40f1dcfdbfbbc91.jpg, createdBy=e1942565806, createdName=12571bd1m76暂无昵称, createdTime=Sat Dec 19 20:19:36 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728600, encodeId=09d21e28600d1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 17 15:37:51 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692144, encodeId=790f16921441f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Feb 22 01:37:51 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924048, encodeId=df721924048f9, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue May 25 09:37:51 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271086, encodeId=b74b12e108688, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 21 06:37:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040787, encodeId=a18b1040e8732, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jul 19 18:37:51 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=909434, encodeId=ec94909434c1, content=说明那些低psa的是神经内分泌前列腺癌啊 tNEPC, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210808/fc552b42cd154706bb2cf25baecb02b2/554ea371740144a7a40f1dcfdbfbbc91.jpg, createdBy=e1942565806, createdName=12571bd1m76暂无昵称, createdTime=Sat Dec 19 20:19:36 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728600, encodeId=09d21e28600d1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Thu Dec 17 15:37:51 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692144, encodeId=790f16921441f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Feb 22 01:37:51 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924048, encodeId=df721924048f9, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Tue May 25 09:37:51 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271086, encodeId=b74b12e108688, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jul 21 06:37:51 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040787, encodeId=a18b1040e8732, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jul 19 18:37:51 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-07-19 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Eur Urol:根治性前列腺癌切除术后前列腺癌结节复发的抢救性淋巴结清除术的长期结果

前列腺癌(PCa)结节复发患者进行抢救性淋巴结清除术(sLND)治疗的长期结果仍旧未知。最近,有研究人员在一个多中心的群体中调查了sLND后的长期肿瘤治疗结果。

Clin Genitourin Cancer:前列腺癌发病率和死亡率与前列腺癌家族史的关系

本研究旨在确定一级亲属(FDR)中的前列腺癌家族史与前列腺癌的发病率和死亡率之间的关系。

J Urol:GnRH激动剂 VS拮抗剂在晚期前列腺癌和心血管疾病患者中的心血管发病率

雄激素剥夺疗法可能会增加患心血管疾病的风险。有限的数据表明,与GnRH激动剂相比,GnRH(促性腺激素释放激素)拮抗剂可能会降低心血管疾病的风险。

Prostate:前列腺癌男性患者前列腺中阿托伐他汀的进入途径和浓度

他汀类药物对前列腺癌在体外和体内都有抗癌作用。目前尚不清楚这是由于全身性降胆固醇还是直接抑制前列腺局部生长。他汀类药物能否进入前列腺也不清楚,理论上,亲脂性的他汀类药物可以通过被动扩散的方式通过富含脂

Cancer:PLCO中前列腺癌总转移和进展率

前列腺、肺、结肠直肠和卵巢(PLCO)癌症筛查试验评估了前列腺特异性抗原筛查和数字直肠检查对前列腺癌死亡率的影响。另一个研究终点是总转移性疾病的负担。

Prostate Cancer P D:前列腺癌检测的种族差异

Stockholm3测试改善了≥2格林森等级分组(GG≥2)前列腺癌的检测,然而,在具有临床实践模式和种族差异的美国群体中还尚未有评估。最近,有研究人员鉴定了不同种族亚群中PC风险情况,并